Abattis Bioceuticals Profit Margin

Abattis Bioceuticals's profit margin stands at -852.4% as of September 2019. That compares with -931940.11% in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of 19.13%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Abattis Bioceuticals reported -852.4% in profit margin versus -931940.11% a year earlier — a 99.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Abattis Bioceuticals sits lower the Healthcare benchmark (19.13%) with a profit margin of -852.4%. That is roughly 4555.5% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -852.4% for Abattis Bioceuticals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Abattis Bioceuticals's profit margin evolved across reporting periods, while the comparison chart places ATTBF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.